Compare Bristol-Myers Squibb Co (BMY) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Direxion Daily TSLA Bull 2X Shares trades at $12.47. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| BMY | TSLL | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $62.37 | $23.03 |
52-Week Low | $42.60 | $10.29 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
TSLL is trading at $12.27, down 6.26% today amid bearish technical signals. The stock faces selling pressure with all 13 moving averages indicating bearish momentum while oscillators remain neutral. Recent news highlights derivative-based ETF strategies and Tesla earnings implications. The company has a future dividend scheduled for June 2026.
The technical outlook appears challenging with strong bearish momentum, though the stock is trading near key support at $12. Fundamental analysis is limited due to unavailable financial ratios. Investors face volatility risks from the leveraged ETF structure and dependency on underlying Tesla performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
